nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemifloxacin—Oedema—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Gemifloxacin—Decreased appetite—Teniposide—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Gemifloxacin—Renal failure—Carmustine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Gemifloxacin—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Gemifloxacin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Gemifloxacin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Gemifloxacin—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Gemifloxacin—Stomatitis—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Gemifloxacin—Rash—Mechlorethamine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Gemifloxacin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Gemifloxacin—Pneumonia—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Gemifloxacin—Flushing—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Gemifloxacin—Anorexia—Fludarabine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Gemifloxacin—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Gemifloxacin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Gemifloxacin—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Gemifloxacin—Stomatitis—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Gemifloxacin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Gemifloxacin—Nausea—Mechlorethamine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Gemifloxacin—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Gemifloxacin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Gemifloxacin—Haemoglobin—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Gemifloxacin—Urticaria—Teniposide—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Gemifloxacin—Glossitis—Methotrexate—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Gemifloxacin—Haemorrhage—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Gemifloxacin—Abdominal pain—Teniposide—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Gemifloxacin—Body temperature increased—Teniposide—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Gemifloxacin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Gemifloxacin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Gemifloxacin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Gemifloxacin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Gemifloxacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Gemifloxacin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Gemifloxacin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Gemifloxacin—Visual impairment—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Gemifloxacin—Fatigue—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Gemifloxacin—Constipation—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Gemifloxacin—Pain—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Gemifloxacin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gemifloxacin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gemifloxacin—Urethral disorder—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gemifloxacin—Eye disorder—Carmustine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Gemifloxacin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Gemifloxacin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Gemifloxacin—Flushing—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Gemifloxacin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Gemifloxacin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Gemifloxacin—Anaemia—Bleomycin—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Gemifloxacin—Asthenia—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Gemifloxacin—Pruritus—Teniposide—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gemifloxacin—Leukopenia—Bleomycin—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gemifloxacin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Gemifloxacin—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gemifloxacin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Gemifloxacin—Mental disorder—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Gemifloxacin—Vaginal infection—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Gemifloxacin—Angiopathy—Vincristine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Gemifloxacin—Diarrhoea—Teniposide—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Gemifloxacin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Gemifloxacin—Myalgia—Bleomycin—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Gemifloxacin—Back pain—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Gemifloxacin—Mental disorder—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Gemifloxacin—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Gemifloxacin—Tremor—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Gemifloxacin—Oedema—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Gemifloxacin—Anaemia—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Gemifloxacin—Back pain—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Gemifloxacin—Vomiting—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gemifloxacin—Asthenia—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gemifloxacin—Rash—Teniposide—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gemifloxacin—Dermatitis—Teniposide—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gemifloxacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gemifloxacin—Headache—Teniposide—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Gemifloxacin—Pruritus—Fludarabine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Gemifloxacin—Back pain—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gemifloxacin—Leukopenia—Carmustine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Gemifloxacin—Anorexia—Bleomycin—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Gemifloxacin—Anaemia—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Gemifloxacin—Photosensitivity—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gemifloxacin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Gemifloxacin—Nausea—Teniposide—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gemifloxacin—Anaemia—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Gemifloxacin—Vertigo—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Gemifloxacin—Leukopenia—Vincristine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gemifloxacin—Myalgia—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gemifloxacin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gemifloxacin—Renal failure acute—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gemifloxacin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Gemifloxacin—Oedema—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Gemifloxacin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Gemifloxacin—Myalgia—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Gemifloxacin—Vomiting—Fludarabine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Gemifloxacin—Rash—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Gemifloxacin—Dermatitis—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Gemifloxacin—Pain—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gemifloxacin—Headache—Fludarabine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gemifloxacin—Tachycardia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gemifloxacin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gemifloxacin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gemifloxacin—Oedema—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gemifloxacin—Anorexia—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gemifloxacin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Gemifloxacin—Oedema—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gemifloxacin—Nausea—Fludarabine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Gemifloxacin—Shock—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gemifloxacin—Urticaria—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gemifloxacin—Anorexia—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gemifloxacin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gemifloxacin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gemifloxacin—Insomnia—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gemifloxacin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gemifloxacin—Dyspnoea—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gemifloxacin—Somnolence—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gemifloxacin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Gemifloxacin—Decreased appetite—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Gemifloxacin—Insomnia—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Gemifloxacin—Pain—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Gemifloxacin—Constipation—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Gemifloxacin—Breast disorder—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gemifloxacin—Decreased appetite—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gemifloxacin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gemifloxacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gemifloxacin—Fatigue—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gemifloxacin—Asthenia—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gemifloxacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gemifloxacin—Pain—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gemifloxacin—Constipation—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gemifloxacin—Pruritus—Bleomycin—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Gemifloxacin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gemifloxacin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gemifloxacin—Fatigue—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gemifloxacin—Pancreatitis—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gemifloxacin—Pain—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gemifloxacin—Constipation—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gemifloxacin—Abdominal pain—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gemifloxacin—Body temperature increased—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gemifloxacin—Body temperature increased—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gemifloxacin—Abdominal pain—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gemifloxacin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gemifloxacin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gemifloxacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gemifloxacin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gemifloxacin—Pneumonia—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gemifloxacin—Vomiting—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Gemifloxacin—Infestation—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Gemifloxacin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Gemifloxacin—Rash—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gemifloxacin—Dermatitis—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gemifloxacin—Asthenia—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Gemifloxacin—Renal failure—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gemifloxacin—Stomatitis—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gemifloxacin—Haematuria—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gemifloxacin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gemifloxacin—Asthenia—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gemifloxacin—Diarrhoea—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gemifloxacin—Nausea—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gemifloxacin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gemifloxacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Gemifloxacin—Dizziness—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gemifloxacin—Haemoglobin—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gemifloxacin—Diarrhoea—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gemifloxacin—Haemorrhage—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gemifloxacin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Gemifloxacin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Gemifloxacin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Gemifloxacin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gemifloxacin—Vomiting—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gemifloxacin—Dizziness—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gemifloxacin—Rash—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gemifloxacin—Dermatitis—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gemifloxacin—Visual impairment—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gemifloxacin—Headache—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gemifloxacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gemifloxacin—Eye disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gemifloxacin—Vomiting—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Gemifloxacin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Gemifloxacin—Rash—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gemifloxacin—Dermatitis—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gemifloxacin—Headache—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Gemifloxacin—Nausea—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Gemifloxacin—Angiopathy—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Gemifloxacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Gemifloxacin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Gemifloxacin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gemifloxacin—Rash—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gemifloxacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gemifloxacin—Headache—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Gemifloxacin—Mental disorder—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Gemifloxacin—Nausea—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Gemifloxacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gemifloxacin—Nausea—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gemifloxacin—Back pain—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gemifloxacin—Anaemia—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gemifloxacin—Vertigo—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Gemifloxacin—Leukopenia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gemifloxacin—Myalgia—Methotrexate—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Gemifloxacin—Arthralgia—Methotrexate—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Gemifloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000958	0.000958	CcSEcCtD
Gemifloxacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000924	0.000924	CcSEcCtD
Gemifloxacin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000906	0.000906	CcSEcCtD
Gemifloxacin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Gemifloxacin—Skin disorder—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Gemifloxacin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000894	0.000894	CcSEcCtD
Gemifloxacin—Anorexia—Methotrexate—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Gemifloxacin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000842	0.000842	CcSEcCtD
Gemifloxacin—Insomnia—Methotrexate—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Gemifloxacin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Gemifloxacin—Somnolence—Methotrexate—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Gemifloxacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Gemifloxacin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000804	0.000804	CcSEcCtD
Gemifloxacin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Gemifloxacin—Fatigue—Methotrexate—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Gemifloxacin—Pain—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Gemifloxacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Gemifloxacin—Urticaria—Methotrexate—lymphatic system cancer	0.000734	0.000734	CcSEcCtD
Gemifloxacin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Gemifloxacin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Gemifloxacin—Asthenia—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Gemifloxacin—Pruritus—Methotrexate—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Gemifloxacin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000632	0.000632	CcSEcCtD
Gemifloxacin—Dizziness—Methotrexate—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Gemifloxacin—Vomiting—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Gemifloxacin—Rash—Methotrexate—lymphatic system cancer	0.000583	0.000583	CcSEcCtD
Gemifloxacin—Dermatitis—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Gemifloxacin—Headache—Methotrexate—lymphatic system cancer	0.000579	0.000579	CcSEcCtD
Gemifloxacin—Nausea—Methotrexate—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
